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Daptomycin is used off-label for enterococcal infections; however, dosing targets for resistance prevention remain undefined.
Doses of 4 to 6 mg/kg of body weight/day approved for staphylococci are likely inadequate against enterococci due to reduced
susceptibility. We modeled daptomycin regimens in vitro to determine the minimum exposure to prevent daptomycin resis-
tance (Dapr) in enterococci. Daptomycin simulations of 4 to 12 mg/kg/day (maximum concentration of drug in serum [Cmax] of
57.8, 93.9, 123.3, 141.1, and 183.7 mg/liter; half-life [t1/2] of 8 h) were tested against one Enterococcus faecium strain (S447) and
one Enterococcus faecalis strain (S613) in a simulated endocardial vegetation pharmacokinetic/pharmacodynamic model over 14
days. Samples were plated on media containing 3 the MIC of daptomycin to detect Dapr. Mutations in genes encoding proteins
associated with cell envelope homeostasis (yycFG and liaFSR) and phospholipid metabolism (cardiolipin synthase [cls] and cy-
clopropane fatty acid synthetase [cfa]) were investigated in Dapr derivatives. Dapr derivatives were assessed for changes in sus-
ceptibility, surface charge, membrane depolarization, cell wall thickness (CWT), and growth rate. Strains S447 and S613 devel-
oped Dapr after simulations of 4 to 8 mg/kg/day but not 10 to 12 mg/kg/day. MICs for Dapr strains ranged from 8 to 256 mg/liter.
Some S613 derivatives developed mutations in liaF or cls. S447 derivatives lacked mutations in these genes. Dapr derivatives
from both strains exhibited lowered growth rates, up to a 72% reduction in daptomycin-induced depolarization and up to 6-nm
increases in CWT (P < 0.01). Peak/MIC and AUC0 –24/MIC ratios (AUC0 –24 is the area under the concentration-time curve from
0 to 24 h) associated with Dapr prevention were 72.1 and 780 for S447 and 144 and 1561 for S613, respectively. Daptomycin doses
of 10 mg/kg/day may be required to prevent Dapr in serious enterococcal infections.
Enterococcus spp. are among the leading causes of nosocomialinfections (1). Vancomycin-resistant Enterococcus faecium has
been recognized as an important multidrug-resistant pathogen
for which new or improved therapies are urgently needed (2, 3).
Daptomycin is a lipopeptide antibiotic with potent in vitro bacte-
ricidal activity against Gram-positive bacteria, including vanco-
mycin-resistant enterococci (VRE). Although daptomycin lacks
an approved indication from the FDA, it is frequently utilized as
an alternative agent for the management of VRE infections. How-
ever, the optimal pharmacokinetic/pharmacodynamic (PK/PD)
targets for resistance prevention and therapeutic success with dap-
tomycin have not been defined (4). In fact, the susceptibility
breakpoint designating resistance in enterococci also remains
questionable; however, for ease of presentation, we will use the
term resistance to refer to nonsusceptible enterococci with dapto-
mycin MICs of 4 mg/liter. Most experts agree that the daptomy-
cin doses of 4 to 6 mg/kg of body weight/day used for staphylo-
coccal infections are likely inadequate for VRE infections due to
reduced susceptibility observed in enterococci (3–5). Daptomycin
MIC50 and MIC90 are 2 and 4 mg/liter for E. faecium, and 0.5 and
1 mg/liter for Enterococcus faecalis versus 0.25 and 0.5 mg/liter for
staphylococci (6). Reports of daptomycin resistance are now be-
coming more common, emphasizing the need for improved dap-
tomycin dosing paradigms to help preserve the utility of this drug
against these difficult to treat pathogens (7–10). Due to the sub-
stantial morbidity and mortality associated with enterococcal in-
fections, it is critical to identify characteristics that correlate with
treatment failure and therefore improve antimicrobial optimiza-
tion and patient outcomes.
In order to derive daptomycin exposure targets for resistance
prevention, we evaluated simulated daptomycin regimens from 4
to 12 mg/kg/day in a 14-day PK/PD model of simulated endocar-
dial vegetations (SEVs) against two daptomycin-susceptible clin-
ical VRE strains (E. faecium S447 and E. faecalis S613). Resistant
strains derived from these models were then subjected to a variety
of phenotypic and genotypic analyses to evaluate characteristics
associated with development of daptomycin resistance.
MATERIALS AND METHODS
Bacterial strains. Two daptomycin-susceptible and vancomycin-resis-
tant enterococcal strains, E. faecalis S613 and E. faecium S447 recovered
from the bloodstream and urine, respectively, of patients before dapto-
mycin therapy, were evaluated (11, 12). Both isolates developed daptomy-
cin-resistant derivatives in vivo during daptomycin therapy (11, 12) and
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have been previously characterized. Additionally, the draft sequences of
both genomes are available (11, 12).
Antimicrobial agents and media. Daptomycin was commercially
purchased (Cubist Pharmaceuticals, Inc., Lexington, MA). Mueller-Hin-
ton broth II (MHB) (Difco, Detroit, MI) with 50 mg/liter of calcium and
12.5 mg/liter magnesium was used for susceptibility testing. Due to the
dependency of daptomycin on calcium for antimicrobial activity and pro-
tein binding of calcium, MHB supplemented to 75 mg/liter of calcium was
used for in vitro SEV model experiments (13). Colony counts were deter-
mined using brain heart infusion agar (BHIA) (Difco, Detroit, MI). Emer-
gence of resistance was assessed with BHIA supplemented with 50 mg/liter
of calcium and 3 MIC of daptomycin of each original strain, E. faecalis
S613 and E. faecium S447.
Susceptibility testing. Daptomycin MICs were determined in dupli-
cate by broth microdilution according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines (14). Any colonies growing on re-
sistance screening plates were evaluated for changes in susceptibility by
broth microdilution.
In vitro PK/PD model. A well-characterized in vitro PK/PD model of
simulated endocardial vegetations (SEVs) previously validated against an
in vivo endocarditis model with Staphylococcus and Enterococcus spp. and
developed by our laboratory was utilized (15). The SEVs were prepared as
previously described using human cryoprecipitate as the source of fibrin,
a platelet suspension, bovine thrombin in siliconized microcentrifuge
tubes, and an organism suspension to reach a final bacterial density of 109
CFU/g. The resultant SEVs were removed from the tubes and suspended
in the model via a sterile monofilament line. The model apparatus was
prefilled with growth media containing human albumin at a concentra-
tion of 3.5 g/dl. Fresh medium was continuously added and removed from
the compartment along with the drug via a peristaltic pump set to simu-
late the half-life of daptomycin. Daptomycin was administered once daily
via an injection port. The following daptomycin exposures with a targeted
half-life (t1/2) of 8 h were evaluated: 4 mg/kg every 24 h (q24h) (peak 57.8
mg/liter) (16), 6 mg/kg q24h (peak 93.9 mg/liter) (17), 8 mg/kg q24h
(peak 123.3 mg/liter) (17), 10 mg/kg q24h (peak 141.1 mg/liter) (17), 12
mg/kg q24h (peak 183.7 mg/liter) (17), and a drug-free growth control
with medium clearance set to mimic an 8-h t1/2 similar to drug experi-
ments. All models were performed in duplicate.
Pharmacokinetic analysis. Pharmacokinetic samples were obtained
and stored as previously described (18). Concentrations of daptomycin
were determined using a validated high-performance liquid chromatog-
raphy assay that conforms to the guidelines set forth by the College of
American Pathologists (17). This assay has demonstrated an interday co-
efficient of variation between 0.6 and 7.3% for all standards. The dapto-
mycin peak concentrations, t1/2, and the area under the concentration-
time curve from 0 to 24 h (AUC0 –24) were determined using PK Analyst
software (version 1.10; MicroMath Scientific Software, Salt Lake City,
UT). The trapezoidal method was utilized to calculate AUC0 –24.
Pharmacodynamic analysis. Two SEVs were removed from each
model at 0, 4, 8, 24, 32, 48, 56, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288,
312, and 336 h. All models were run in duplicate. The SEVs were homog-
enized and diluted in cold saline to be plated on BHIA plates. For all
samples, antimicrobial carryover was accounted for by serial dilution of
the plated samples. If the anticipated dilution was near the MIC, samples
were processed via vacuum filtration and washed through a 0.45-m filter
(Pall Corporation, Ann Arbor, MI) with normal saline to remove any
daptomycin. The limit of detection for determination of colony counts
was 1 log10 CFU/g. The plates were incubated at 35°C for 24 h, and the
viable CFU were enumerated. Changes in log10 CFU/g were plotted
against time to construct curves to describe the antibacterial activity of the
simulated regimens. Bactericidal activity (99.9% kill) was defined as a
3-log10 CFU/g reduction in colony count from the initial inoculum.
Bacteriostatic activity was defined as a 3-log10 CFU/g reduction in col-
ony count from the initial inoculum, while inactivity was defined as no
observed reductions in bacterial counts from the initial inoculum.
Changes in CFU/g over time were reported graphically as the mean and
standard deviation of the duplicate models for each exposure.
Resistance. Emergence of resistance was evaluated at multiple time
points throughout the simulation by plating 100-l samples of homoge-
nized clots at each time point on BHIA plates supplemented with 50
mg/liter of calcium and daptomycin at a concentration 3 the MIC for
the specific test organism. The plates were examined for growth after 48 h
of incubation at 35°C. Colonies growing on resistance screening plates
were evaluated for changes in MIC by broth microdilution. Isolates with a
daptomycin MIC of 4 mg/liter were saved in glycerol tubes at 80°C for
further phenotypic and genetic workup.
Characterization of daptomycin-resistant derivatives. (i) Cationic
peptide and daptomycin binding determination. When daptomycin is
bound with elemental calcium, the daptomycin-calcium complex is pos-
itively charged, and its degree of binding with the cell membrane has been
postulated to be dependent on the attractive forces between the drug and
cell surface (19). Cytochrome c is a cationic peptide that has been used as
a surrogate marker for changes in surface charge. A cytochrome c binding
study was performed by the method of Kraus et al. (20) Resistant deriva-
tives from each model were evaluated for changes in cytochrome c binding
and compared to the unexposed parent strain.
(ii) Binding of fluorescent daptomycin. Bacteria were grown to an
optical density at 600 nm (OD600) of 0.6 and then incubated with 16
g/ml daptomycin– boron-dipyrromethene (bodipy) for 10 min, washed
three times in medium to remove unincorporated label, stained with 2
g/ml DAPI (4,6-diamidino-2-phenylindole), and placed on a 1.2% aga-
rose pad for imaging in an Applied Precision deconvolution fluorescence
microscope as described previously (21). For quantitation of daptomycin-
bodipy fluorescence, images from each sample were collected using iden-
tical camera exposures. Cell Profiler was used to measure the average
fluorescence intensity of individual pixels for 200 cells for the parent
and resistant strains. The average fluorescence intensity of individual pix-
els for the background was also measured and subtracted from the cells to
generate an accurate measurement of daptomycin-bodipy binding. Dap-
tomycin binding to the resistant strains was compared to the binding
observed with the parent strains.
(iii) Binding of fluorescent cathelicidin LL37. Bacteria were grown in
LB broth to an OD600 of 0.5 to 0.6, diluted 1:1 in phenol red-free RPMI
medium (Invitrogen) in a final volume of 200 l with 6-carboxytetram-
ethylrhodamine (TAMRA)-labeled LL37 (American Peptide, Sunnyvale,
CA) (TAMRA-LL37) to a final concentration of 1 M for E. faecium and
32 M for E. faecalis, and incubated for 45 min at 37°C with shaking.
These concentrations were chosen based on previous LL37 susceptibility
data in order to maintain bacterial integrity for microscopy. Bacteria were
pelleted, washed three times with RPMI medium, counterstained with
DAPI (2 g/ml) in the final wash, and visualized using a Delta Vision
Deconvolution microscope (Applied Precision, Inc., Issaquah, WA).
(iv) Determination of cytoplasmic membrane depolarization. The
ability of daptomycin to depolarize the cytoplasmic membrane of par-
ent and resistant strains was carried out as previously described using
a kinetic spectrofluorometric assay (22). Upon membrane potential
dissipation from daptomycin or another cationic antimicrobial pep-
tide, 3,3-dipropylthiadicarbocyanine iodide (DiSC3) is released from
the cell membrane into the surrounding medium, causing an increase in
the fluorescence intensity at a wavelength of 670 nm. Daptomycin concentra-
tions of 11.3 mg/liter (correlating with an average free peak of a 10-mg/kg/day
dose) were utilized for each experiment. The membrane depolarization pro-
files over 1 h of the resistant strains and the parent strains were determined
and compared. Nisin was used as a positive control to demonstrate that the
assay was functioning properly.
(v) Cell wall thickness. Cell wall thickness was determined by trans-
mission electron microscopy (TEM) as described previously (23). Ultra-
thin sections were evaluated at a magnification of 48,000 with a JEOL
100CX electron microscope, and images were captured with a MegaView
III side-mounted digital camera. The resulting images were analyzed us-
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ing ImageJ 1.39t software. Cell wall thickness was determined for at least
15 cells per sample using four separate quadrants of each cell for a total of
100 measurements per sample.
(vi) Growth kinetics. Bacterial growth kinetics of daptomycin-resis-
tant strains derived from the final time points of each model were evalu-
ated and compared to the parent strains. Briefly, using a 96-well, flat-
bottom plate, 200 l of MHB was inoculated with 106 CFU/ml of each test
organism in triplicate. The plate was incubated in a spectrophotometer at
37°C for 8 h, and the optical density at 600 nm was automatically mixed
and measured every 15 min. Turbidity measurements were plotted over
time to construct growth curves. Daptomycin-resistant strains were com-
pared to unexposed parent strains.
(vii) Mutation screening by PCR. Mutations in genes previously as-
sociated with daptomycin resistance were evaluated using Sanger se-
quencing of PCR products obtained from the entire open reading frame.
The following genes were investigated: (i) yycFG encoding a predicted
two-component regulatory system involved in cell wall homeostasis (yycF
and yycG encode the putative response regulator and histidine kinase of
the system, respectively) (12); (ii) liaFSR, encoding a putative three-com-
ponent regulatory system that is part of the cell envelope response to
antibiotics and antimicrobial peptides (11, 24); and (iii) cls and cfa, en-
coding two enzymes (cardiolipin synthase and cyclopropane fatty acid
synthase, respectively) that are likely to be involved in cell membrane
phospholipid metabolism and have been previously associated with dap-
tomycin resistance in E. faecalis (11) and E. faecium (11, 12, 25). A non-
synonymous mutation was defined as a nucleotide change that resulted in
an amino acid substitution not present in daptomycin-susceptible paren-
tal enterococci (S447 and S613), whose genomes are sequenced and pub-
licly available. E. faecalis V583 (26) and E. faecium DO (27) (closed ge-
nomes) were used as the template for sequence assembly. Primers utilized
to amplify the genes above are listed in Table 1.
(viii) Statistical analysis. Changes in CFU/g, cytochrome c binding,
daptomycin-bodipy binding, TAMRA-LL37 binding, total daptomycin-
induced depolarization, and growth curve AUCs were compared by one-
way analysis of variance with Tukey’s posthoc test or by t test as appropri-
ate. A P value of 0.05 was considered significant. All statistical analyses
were performed using SPSS statistical software (release 21.0; SPSS, Inc.,
Chicago, IL).
RESULTS
Susceptibility testing. Daptomycin MICs for E. faecium S447 and
E. faecalis S613 were 2 and 1 mg/liter, respectively. MICs of dap-
tomycin-resistant derivatives recovered from the in vitro models
ranged from 8 to 256 mg/liter.
In vitro PK/PD model. Observed PK parameters and achieved
PK/PD ratios are summarized in Table 2. Quantitative changes in
log10 CFU/g for each regimen are illustrated in Fig. 1 and 2 for each
TABLE 1 Oligonucleotide primers used in this study
Bacterial species and gene(s) Primera Sequence Product size (bp)
E. faecalis




cls cls-F ACATCAAAAAGACCCCCTCA 1,806
cls-R AAAAGATGTCCCTTTTTCACA
E. faecium




yycF yycF-F GGGGATGCGAAAGAAGAAGCA 1,539
yycF-R AAGAGCCCCGATAACGGCAT
yycG yycG-F AGAAGAGGCAGCACCTGCGGA 2,533
yycG-R AAGGCGCATTATAGGCCAACTCAAA
cls cls-F TATTCACCTTGGTAGGCTTC 1,554
cls-R TTTTTGTCACAGTCCCTTTAATCTT
cfa cfa-F GCCAACTCAAGTGTTTGCGG 2,400
cfa-R AAGAGCGCTGTTCGCTACTG
a The forward and reverse primers are indicated by the letter F and R, respectively, at the end of the primer name.




E. faecium S447 with a DAP MIC
of 2 mg/literb
E. faecalis S613 with a DAP
MIC of 1 mg/liter
Cmax t1/2 AUC0–24 AUC0–24/MIC Peak/MIC AUC/MIC Peak/MIC
12 184.1  2.5 7.75  0.35 2,036.3  145.1 1,018.15 92.05 2,036.3 184.1
10 144.3  1.8 8.0  0.14 1,561.7  37.2 780.85 72.15 1,561.7 144.3
8 122.4  0.1 8.15  0.07 1,342.9  7.6 671.45 61.2 1,342.9 122.4
6 94.3  1.9 7.25  0.21 959.1  35.7 479.55 47.15 959.1 94.3
4 57.6  1.7 8.05  0.07 627.3  22.9 313.65 28.8 627.3 57.6
a Cmax, maximum concentration of drug in serum; t1/2, half-life; AUC0 –24, area under the concentration-time curve from 0 to 24 h.
b DAP, daptomycin.
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organism. Against E. faecium S447, all regimens were bactericidal
within the first 24 h, but only 10- and 12-mg/kg/day exposures
remained bactericidal for the duration of the models. These expo-
sures produced similar reductions in bacterial densities (P  0.55)
by 336 h but offered significantly greater CFU/g reductions com-
pared to 4- to 8-mg/kg/day regimens (P  0.0005). Against E.
faecalis S613, 6- to 12-mg/kg/day regimens were bactericidal
within the first 24 h, but only 12-mg/kg/day exposures remained
bactericidal for the duration of the model. This regimen main-
tained statistically superior CFU/g reductions compared to 4- to
10-mg/kg/day regimens by 336 h (P  0.0005). Daptomycin re-
sistance, defined as recovery of isolates with an MIC of 4 mg/
liter, emerged in both strains from models simulating 4-, 6-, and
8-mg/kg/day regimens but not during simulated exposures of 10
and 12 mg/kg/day. Resistant isolates were observed as early as 120
h and 144 h from the E. faecalis S613 strain and the E. faecium S447
strain, respectively. The peak/MIC and AUC0 –24/MIC ratios ob-
served with the 10-mg/kg/day simulations were 72 and 781 for
strain S447 and 144 and 1,562 for strain S613, respectively.
Characterization of daptomycin-resistant derivatives. (i)
Cationic peptide and daptomycin binding determination. Cyto-
chrome c binding studies revealed a significant reduction in the
bound fraction of cytochrome c in daptomycin-resistant isolates
derived from our models. On average, E. faecalis S613-derived
resistant strains bound 42% (median) less cytochrome c than the
parent strain, with a range from 2% to 94% (P  0.01). E. faecium
S447-derived resistant strains bound 28% (median) less cyto-
chrome c than the parent strain with a range of 13% to 40%. This
difference was significant for some of the S447-derived resistant
strains tested, but not all.
(ii) Binding of fluorescent daptomycin. Two representative
daptomycin-resistant derivatives were chosen from the SEV
model for microscopy experiments: (i) a derivative of E. faecalis
S613 that was obtained on day 10 at a simulated dose of 4 mg/kg
(E. faecalis S613D4 harboring an insertion of isoleucine in position
177 of the putative LiaF protein with an MIC of 16 g/ml), and (ii)
a derivative of E. faecium S447, obtained on day 14 at a simulated
dose of 4 mg/kg (E. faecium S447D4 with no mutations in target
genes with a MIC of 128 g/ml). Results of daptomycin-bodipy
binding for selected parent and derivative strains are depicted in
Fig. 3. The mean fluorescent intensity of bound daptomycin-bo-
dipy at 16 g/ml was 2.3 higher for E. faecalis S613 than for E.
faecalis S613D4 (671.29  11.80 versus 282.16  19.40, respec-
tively [mean  standard error shown]; P  0.0001). Similarly, the
mean fluorescent intensity of bound daptomycin-bodipy for E.
faecium S447 cells was 334.83  5.65 but was below the level of
detection for E. faecium S447D4.
(iii) Binding of fluorescent LL37. Changes in fluorescent la-
beled LL37 binding between E. faecalis S613 and E. faecium S447
versus their daptomycin-resistant derivatives (E. faecalis S613D4
and E. faecium S447D4, respectively) are illustrated in Fig. 4. Sim-
ilar to daptomycin binding, TAMRA-labeled LL37 (TAMRA-
LL37) was found to bind less to their daptomycin-resistant deriv-
atives obtained from the SEV model. The mean fluorescence
intensity of bound TAMRA-LL37 at 1 M was 3.4 higher in E.
faecium S447 than in E. faecium S447D4 (601.99  37.99 versus
177.30  17.08, respectively [mean  standard error shown]; P 
0.0001). Similarly, the mean fluorescence intensity of bound
TAMRA-LL37 at 32 M in E. faecalis S613 cells was 2.4 higher
than those in E. faecalis S613D4 (154.35  20.83 versus 65.09 
17.08, respectively; P  0.05).
(iv) Determination of cytoplasmic membrane depolariza-
tion. Daptomycin-induced membrane depolarization of parent
strains and selected resistant derivatives is depicted in Fig. 5A and
FIG 2 Pharmacodynamic response of Enterococcus faecalis S613 in the SEV
model to different dose exposures of daptomycin over 14 days. Data are pre-
sented as mean CFU/g with error bars indicating standard deviations of the
means of results from duplicate experiments.
FIG 1 Pharmacodynamic response of Enterococcus faecium S447 in the SEV
model to different dose exposures of daptomycin (DAP) over 14 days. Data are
presented as mean CFU/g with error bars indicating standard deviations of the
means of results from duplicate experiments.
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B. Both the total amount of membrane depolarization and the rate
of depolarization were substantially reduced among daptomycin-
resistant strains. The total percentage depolarization was 19.7% to
37.2% for E. faecalis S613 derivatives and 12.8% to 53.3% in E.
faecium S447-derived strains compared to 100% for both parent
strains (P  0.0001).
(v) Cell wall thickness. Transmission electron microscopy
(Fig. 6 and 7) revealed multiple morphological abnormalities in E.
faecium S447D4 compared to its daptomycin-susceptible parental
strain. E. faecium S447D4 was found to have a 4.5-nm increase in
cell wall thickness compared to E. faecium S447 (31.7  4.9 nm
versus 27.2  4.9 nm, respectively; P  0.001), while the cell wall
thickness of E. faecalis S613D4 increased by an average of 6.2 nm
compared to S613 (26.2  4.4 nm versus 20.0  4.1 nm, respec-
tively; P  0.001). Qualitatively, the daptomycin-resistant deriv-
atives of both species were found in clusters, demonstrating poor
cell separation and abnormal septum formation. Another promi-
nent finding observed in this study was the development of abnormal
protrusions from the cell wall. These abnormalities have previously
been reported in daptomycin-resistant VRE, but it is unclear whether
they are a cause or effect of daptomycin resistance (11, 24).
(vi) Growth kinetics. Growth kinetic analysis revealed that the
majority of the resistant derivatives from either strain developed
daptomycin resistance at the cost of fitness. Interestingly, the de-
gree of growth rate inhibition appeared to be proportional to the
daptomycin exposures in the model from which they were de-
rived. Daptomycin-resistant strains derived from the 4-mg/kg/
day simulations had less growth rate inhibition, while resistant
derivatives from 6- and 8-mg/kg/day simulations tended to have
lower growth rates. The growth rates of E. faecalis S613D4 (harbor-
ing an insertion in liaF) and an S613-derived mutant with a three-
codon deletion in cls were unchanged compared to that of the
parent strain (P  0.28 and P  0.055, respectively). The time to
mid-exponential growth was 286  3.15 min versus 323  34.5
min for E. faecalis S613 and its resistant derivatives, respectively,
and 338  0.9 min versus 405  50.2 min for E. faecium S447 and
its resistant derivatives, respectively. Exponential-phase doubling
times for strains S613 and S447 were both 50 min. E. faecalis S613-
derived strains demonstrated a median doubling time of 75 min
with a range of 52 to 91 min. E. faecium S447-derived strains
demonstrated a median mid-exponential doubling time of 60 min
with a range of 57 to 74 min. The overall growth rate, assessed by
comparison of the area under the growth-versus-time curves, was
significantly lower in 50% of E. faecalis S613-derived strains com-
pared to S613 (P  0.001) and 83% of E. faecium S447-derived
strains relative to S447 (P  0.001).
(vii) Mutation screening by PCR. Mutations in liaFSR and cls
were assessed in all derivative strains. Additionally, yycFG and cfa
were also evaluated in E. faecium derivatives. The mutations iden-
tified are summarized in Table 3. Nonsynonymous point muta-
tions in liaF and cls were identified in six E. faecalis S613 mutants
derived from the 4-mg/kg/day simulations but were not found in
strains derived from other exposures. No mutations in the target
genes were identified in E. faecium S447-derived strains.
DISCUSSION
Infections with VRE are a major therapeutic challenge due to in-
trinsic resistance to multiple antibiotic classes, a paucity of bacte-
ricidal agents, and the rapid emergence of acquired antibiotic re-
sistance. Antimicrobial dose optimization is necessary for the
preservation of the clinical utility of currently available antimicro-
bials, but there are insufficient data to recommend resistance
prevention dosing targets for most drugs. In this study, we have
demonstrated that for daptomycin-susceptible strains of vanco-
mycin-resistant E. faecium and E. faecalis, daptomycin exposures
associated with doses of at least 10 mg/kg/day are likely to be
FIG 3 Membrane-bound fluorescently labeled daptomycin (green) in the parent strains (E. faecium S447 and E. faecalis S613) (left images) and representative
daptomycin-resistant (Dap-R) strains (right images). Cells are stained with DAPI (blue).
FIG 4 Membrane-bound fluorescently labeled human cathelicidin LL37 (red) in the parent strains (E. faecium S447 and E. faecalis S613) (left images) and
representative daptomycin-resistant (Dap-R) strains (right images). Cells are stained with DAPI (blue).
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required to prevent resistance emergence. These doses were asso-
ciated with an AUC0 –24/MIC ratio of 781 for E. faecium S447 and
1,562 for E. faecalis S613. These exposures are clinically achievable
and have been shown to be safe in multiple studies (17, 28–30).
While we did not detect resistant derivatives from the models at
10-mg/kg/day simulations, bacterial regrowth began to occur in
E. faecalis S613 after 240 h in both the 10- and 12-mg/kg/day
simulations (Fig. 2). While this regrowth phenomenon may occur
in in vitro models in the absence of meaningful susceptibility
changes, it is possible that if the model was run for longer that
resistance may have emerged from even these higher exposures.
It is interesting that there is a 2-fold-higher daptomycin resis-
tance prevention AUC0 –24/MIC ratio in E. faecalis compared to E.
faecium; this is associated with a much higher intrinsic resistance
to the cationic antimicrobial peptide LL37 in the former species,
even though daptomycin MIC50/MIC90 values are considerably
higher in E. faecium (2/4 mg/liter versus 0.5/1 mg/liter) (31). The
increased intrinsic resistance to antimicrobial peptides in E. faeca-
lis may be related to the fact that it causes 90% of enterococcal
endocarditis, compared to 5 to 10% for E. faecium (32). Reflective
of this difference in LL37 MIC, which approximates 1 to 4 M in
E. faecium and 16 to 64 M in E. faecalis, was the concentrations of
LL37 used in the LL37 binding assay experiments. These findings
highlight the cross-resistance between endogenous antimicrobial
peptides produced by innate immune defenses and pharmaceuti-
cal antibiotics like daptomycin. It also points to the important role
that in vivo peptide exposure might play in driving antibiotic re-
sistance in the absence of administered drugs. Peptide-mediated
predisposition for daptomycin resistance in vivo makes achieving
the critical AUC0 –24/MIC threshold of utmost importance in the
treatment of infective endocarditis, where suboptimal exposure to
cationic antimicrobial peptides is likely.
The mechanisms of daptomycin resistance in enterococci have
not been fully elucidated. It appears that resistance to daptomycin can
emerge through a variety of genetic pathways (33), but a common
theme involves mutations in two group of genes: (i) genes involved in
cell envelope homeostasis (yycFG and liaFSR systems) and (ii) genes
encoding enzymes involved in phospholipid metabolism (i.e., cls,
gdpD, and cfa encoding cardiolipin synthase, glycerophosphodiester
phosphodiesterase, and cyclopropane fatty acid synthase, respec-
tively) (11, 12, 24, 34). However, the absence of mutations in some of
these target genes in some of our resistant derivatives suggests that
alternative genetic pathways remain to be discovered. In E. faecalis
S613, mutations in liaF and cls were observed in resistant strains
derived from the 4-mg/kg/day exposures. However, these muta-
tions, although present in the same genes, were different from
those previously described under daptomycin exposure in vivo
(11). Moreover, resistant derivatives of E. faecium S447 selected in
the SEV model harbored none of the mutations in yycG, cls, or cfa
previously described in an S447-resistant derivative (designated
R446) obtained from the bloodstream of a patient after daptomy-
cin therapy. Our findings suggest that there are multiple alterna-
tive genetic pathways leading to daptomycin resistance. Our re-
sults also highlight the remarkable ability of enterococci to adapt
to the attack of antimicrobial peptides.
Recent insights into the complex mechanism of daptomycin
resistance suggest that in certain enterococcal strains, the mecha-
nism of resistance may not involve “repulsion” of cation-deco-
rated daptomycin from the cell surface, as previously shown. Tran
et al. recently postulated that diversion of daptomycin from the
bacterial septum with subsequent “trapping” of the antibiotic
away from septal areas may be an alternative mediator of dapto-
mycin resistance in E. faecalis (24). This antibiotic diversion was
associated with redistribution of cardiolipin arrays away from the
septum, which appeared to be mediated by an Ile177 deletion in
the predicted LiaF protein. Interestingly, instead of an Ile177 de-
letion, our E. faecalis S613-derived mutant (S613D4) harbored an
Ile insertion at the same position. However, our microscopy data
with bodipy-labeled daptomycin and TAMRA-labeled LL37 indi-
cate that the mechanism of daptomycin resistance for this mutant
involves the classical “repulsion” of the antibiotic from the cell
surface, highlighting different strategies under various conditions.
Resistant derivatives also developed thicker cell walls with more
septum formation and poor cell separation. It is believed that
some organisms may use this strategy of forming “false” division
septa in order to draw daptomycin molecules away from critical
binding sites at the “true” division septum. It is possible that di-
FIG 5 Daptomycin-induced membrane depolarization over 1 h in E. faecium
S447 and resistant derivatives (A) and E. faecalis S613 and resistant derivatives
(B). Nisin (25 mg/liter) was used as a positive control for membrane depolar-
ization (thin solid line). The parent strain exposed to daptomycin (11.3 mg/
liter) (line of long dashes), average resistant derivative exposed to daptomycin
(11.3 mg/liter) (thick solid line) with upper and lower standard deviation
(lines of short dashes), and negative control (dotted line) are shown. The
emission wavelength is shown on the y axes.
Werth et al.
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version of daptomycin from critical sites is an initial strategy at
early stages of the development of daptomycin resistance. While
daptomycin is not shown to be diverted in the daptomycin-resis-
tant mutant E. faecalis S613D4 (as previously shown in other
strains), the genotypic characterization of such resistant deriva-
tives suggest that different mutations than those previously de-
scribed in vivo occurred, making comparisons difficult to estab-
lish. Additionally, other unknown mutations may have occurred,
and their role in manifestation of this phenotype is unclear at this
time. Given that it was not feasible to perform fluorescent drug
FIG 6 TEM of the parent strain E. faecium S447 illustrating baseline cell wall thickness and the absence of abnormal surface projections and division septa. Bars,
500 nm.
FIG 7 TEM of the parent strain E. faecium S447D4 illustrating increased cell wall thickness and the presence of abnormal surface projections and division septa.
Bars, 500 nm.
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binding studies or TEM on more than two of the daptomycin-
resistant derivatives, it may also be possible that some of the other
strains would have behaved differently in these experiments. Fur-
ther studies are warranted to clarify the genetic changes associated
with these phenotypes in E. faecalis (24).
To our knowledge, this is the first study that explores the dap-
tomycin resistance prevention breakpoint in enterococci using
clinically relevant drug exposures over the substantial time period
of 14 days. Based on our observations, it is clear that the dose of
daptomycin for the management of VRE infections and preven-
tion of resistance is much higher than the labeled dose of 6 mg/kg/
day indicated for staphylococcal bacteremia and is likely around
10 mg/kg/day for average patients with MICs in the susceptible
range. However, this study is limited to some extent by the num-
ber of strains tested and the potential variability between entero-
coccal species (i.e., E. faecium versus E. faecalis). Furthermore, this
resistance prevention breakpoint was derived in a model with very
high bacterial densities (9 log10 CFU/g), so these data may be more
representative of serious high-inoculum infections such as infec-
tive endocarditis and less relevant to more-benign infections.
Emerging data suggest that certain strains of VRE with genetic
predisposition toward daptomycin resistance, specifically those
with liaFSR mutations, may require clinically unachievable dap-
tomycin exposures to prevent resistance. Further research in this
area should focus on characterizing this resistance prevention ex-
posure in other strains and exploring strategies, such as combina-
tion therapy, to lower this breakpoint.
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